RT Journal Article
SR Electronic
T1 Protein Abundance of Class III Beta-tubulin but Not Δ2-Alpha-Tubulin or Tau is Related to Paclitaxel Response in Carcinomas of Unknown Primary Site
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1161
OP 1167
VO 28
IS 2B
A1 PASCAL SÈVE
A1 TONY REIMAN
A1 SYLVIE ISAAC
A1 VÉRONIQUE TRILLET-LENOIR
A1 LAURENCE LAFANÉCHÈRE
A1 MICHAEL SAWYER
A1 CHARLES DUMONTET
YR 2008
UL http://ar.iiarjournals.org/content/28/2B/1161.abstract
AB Aim: To determine the prognostic value of microtubule component expression in tumors of patients with carcinomas of unknown primary site (CUP). Patients and Methods: Class III β-tubulin, Δ2-α-tubulin and tau protein were examined immunohistochemically in 51 CUP tumors from patients receiving paclitaxel and compared with their response to treatment. Results: The overall response rate was 18.4% among 49 evaluable patients. Δ2-α-Tubulin and tau were not correlated with response or patient outcome. High class III β-tubulin expression was correlated with both resistance to chemotherapy and shorter overall survival, while there was no relation with progression-free survival. In multivariate analysis taking into account clinical factors, class III β-tubulin expression was independently correlated with overall survival. Conclusion: These findings show that in tumor cells a high level of expression of class III β-tubulin, but not Δ2-α-tubulin or tau, is associated with resistance to paclitaxel and a poor prognosis in CUP patients receiving paclitaxel. Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved